04:29:25 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-09-10 Årsstämma 2025
2024-05-30 Bokslutskommuniké 2024
2024-02-28 Kvartalsrapport 2024-Q3
2023-11-28 Kvartalsrapport 2024-Q2
2023-09-08 Ordinarie utdelning QCORE 0.00 SEK
2023-09-07 Årsstämma 2024
2023-08-30 Kvartalsrapport 2024-Q1
2023-05-30 Bokslutskommuniké 2023
2023-02-28 Kvartalsrapport 2023-Q3
2022-11-28 Kvartalsrapport 2023-Q2
2022-09-08 Ordinarie utdelning QCORE 0.00 SEK
2022-09-07 Årsstämma 2023
2022-08-30 Kvartalsrapport 2023-Q1
2022-06-08 Bokslutskommuniké 2022
2022-02-28 Kvartalsrapport 2022-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlucore är verksamt inom teknikbranschen. Bolaget är specialiserat inom utveckling av 3d-visualisering. Programvaran är egenutvecklad och används huvudsakligen för att identifiera och analysera strukturer och mönster. Mjukvaran gör det möjligt för användaren att utforska och analysera stora datamängder, interaktivt och i realtid med användning av en vanlig dator. Kunderna består av företagskunder verksamma inom forskning och diagnostik. Qlucore grundades 2007 och har sitt huvudkontor i Lund.
2023-08-21 10:00:00

– Receives new funding to drive implementation in cancer care
  
Qlucore, listed on Nasdaq First North and a developer of visualization-based software for research-focused data analysis and precision diagnostics, has received a grant of SEK 200,000 from innovation agency Vinnova through the strategic innovation program Medtech4Health. The program's mission is to implement more medical technology solutions in healthcare for the benefit of patients.

The project funded by Medtech4Health aims to enhance Qlucore Diagnostics' ability to protect patient data and ensure data security. 

Qlucore Diagnostics is planned to be launched in 2025 as a CE-marked in vitro diagnostic medical device. This means that Qlucore Diagnostics will be authorized for clinical use in hospital laboratories.

"Dividing cancer types into various subgroups provides personalized cancer treatment. This could result in more effective treatment and, in some cases, spare patients from demanding treatments with severe side effects”, says Carl-Johan Ivarsson, CEO of Qlucore and continues:

“We are pleased that Medtech4Health recognizes the potential of Qlucore Diagnostics in healthcare, enabling more precise cancer treatment for cancer patients.”

The Qlucore Insights software, designed for research and enabling early testing and evaluation, is already available on the market. Currently, four models are being tested; two for different types of leukemia, one for lung cancer, and one for bladder cancer. Through these classification models, cancer types can be divided into several subgroups, leading to improved information.

Medtech4Health works to implement more medical technology ideas and solutions in healthcare for the benefit of patients. Through collaboration with healthcare providers, academia, and the industry, value is created for patients and the medical technology sector is strengthened. Medtech4Health is funded by the Swedish government through the innovation agency Vinnova, the Swedish Energy Agency, the Swedish Research Council for Sustainable Development (Formas), and the program's participating partners. Learn more at www.medtech4health.se